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Abstract
Background: Role of immune system in protecting the host from cancer is well established. Growing cancer however
subverts immune response towards Th2 type and escape from antitumor mechanism of the host. Activation of both innate
and Th1 type response is crucial for host antitumor activity. In our previous study it was found, that Mycobacterium indicus
pranii (MIP) also known as M. w induces Th1 type response and activates macrophages in animal model of tuberculosis.
Hence, we studied the immunotherapeutic potential of MIP in mouse tumor model and the underlying mechanisms for its
antitumor activity.
Methodology and Principal Findings: Tumors were implanted by injecting B16F10 melanoma cells subcutaneously into
C57BL/6 mice. Using the optimized dose and treatment regimes, anti-tumor efficacy of heat killed MIP was evaluated. In MIP
treated group, tumor appeared in only 50–60% of mice, tumor growth was delayed and tumor volume was less as
compared to control. MIP mediated immune activation was analysed in the tumor microenvironment, tumor draining lymph
node and spleen. Induction of Th1 response and higher infiltration of immune cells in the tumor microenvironment was
observed in MIP treated mice. A large fraction of these immune cells were in activated state as confirmed by phenotypic and
functional analysis. Interestingly, percentage of Treg cells in the tumor milieu of treated mice was less. We also evaluated
efficacy of MIP along with chemotherapy and found a better response as compared to chemotherapy alone.
Conclusion: MIP therapy is effective in protecting mice from tumor. It activates the immune cells, increases their infiltration
in tumor, and abrogates tumor mediated immune suppression.
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Introduction
Immune system plays a crucial role in protecting the host
against cancer. There is strong evidence for the existence of an
effective cancer immunosurveillance process in human and mice.
In tumor bearing host however, immune system is often not able
to mount an effective response, primarily because of negative
regulatory mechanisms employed by growing cancer [1]. Th1
branch of the immune system, which employs T cells, NK cells
and macrophages, play major role in combating cancer but
growing cancers actively suppress immune response and disregu-
lates the activity of these effector cells [2,3].
Since long, bacteria and bacterial products have been tried for
the treatment of cancer. Starting from the practical observation of
tumor regression in individuals with concomitant bacterial
infection and systematic efforts of William Coley in this direction,
the field has developed into some standard clinical practices, such
as the use of BCG for the treatment of superficial bladder cancer
for over 25 years [4]. BCG-cell wall components has been
administered to patients for postoperative treatment of cancer,
producing good prognosis [5,6]. Mycobacterium vaccae was also
studied in few clinical trials [7]. Indeed, it has been observed that
different mycobacterial species differ widely in their antitumor
potential and there is need of sincere efforts to look for potent
candidate species. A related organism Mycobacterium indicus pranii
(MIP) is non-pathogenic, soil derived, rapidly growing, atypical
mycobacterium [8]. Polyphasic taxonomic analysis has established
it as a distinct species [9]. There are some key differences between
BCG and MIP. BCG is attenuated form of pathogenic organism
M. bovis, survives in host cells for months [10] and has been shown
to cause toxicity in some patients while MIP is cleared from the
host body in few weeks and is non-pathogenic [11].
Couple of small clinical studies, where MIP was given to lung
cancer and bladder cancer patients, indicated its beneficial effect
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tuberculosis we had found that MIP induces Th1 type response as
indicated by the activation of both CD4+ and CD8+ T cells and
also macrophages which control growth and multiplication of M.tb
[11]. As induction of Th1 type of immune response is crucial to
overcome the immuno-suppressive tumor microenvironment, we
sought to analyse the immunotherapeutic potential of MIP in
mouse model of tumor. It was observed that tumor growth was
delayed and volume of tumors were significantly less in the MIP
treated group as compared to control. Tumor appeared in only
50–60% of the mice in MIP treated group and in these mice
tumors were infiltrated with higher number of CD4+ and CD8+T
cells, NK and NKT cells, macrophages and dendritic cells. The
immune cells were in functionally active state in the MIP treated
group, as there was higher induction of proinflammatory cytokines
and increased cytotoxicity towards target tumor cells as compared
to control. Further, significantly less percentage of regulatory T
cells were found in the tumor mass of MIP treated mice as
compared to control tumor bearing mice.
Materials and Methods
Animal
Inbred C57BL/6 mice at 6–8 weeks of age were obtained from
the animal facility of the National Institute of Immunology, New
Delhi, India, where animals are bred and housed in agreement
with the guidelines of the Institute’s Animal Ethics Committee. All
animal experiments were performed in accordance with Animal
Ethics Committee’s guidelines (Approval ID of the project -
IAEC#/205/08).
Cell lines
B16F10 melanoma cell line (obtained from American Type
Culture Collection, ATCC number: CRL-6475) was cultured in
DMEM medium. YAC-1 lymphoma cells (obtained from National
Centre for Cell Science, Pune, India), were cultured in RPMI
1640 medium. Culture media was supplemented with 10% FBS
and 1% antibiotic-antimycotic solution, and cells were grown in
37uC incubator with 5% CO2/95% humidified air. These cells
were free of mycoplasma contamination.
Inactivation of Mycobacterium indicus pranii (MIP)
MIP, previously known as M. w was maintained on Lowenstein-
Jensen medium (LJ) slants (BD Difco) and kept at 280uC. It was
cultured in Middlebrook 7H9 medium (BD Difco) with 0.2%
glycerol, 0.05% Tween 80 and 10% albumin-dextrose-catalase
enrichment (BD Difco) as a shake flask culture. Bacteria were
harvested in the log growth phase by centrifugation at 8406g for
15 min, washed twice with PBS, and suspended in saline at the
desired concentration. These were then inactivated by autoclaving
for 20 min at a pressure of 15 lb/in
2. These inactivated bacteria
were used for immunisation & treatment in the tumor bearing
mice.
Tumor implantation
Initially different numbers of B16F10 cells were subcutaneously
injected in the right flank of syngeneic C57BL/6 mice to
determine an appropriate tumor burden. For all subsequent
experiments, 30,000 B16F10 cells were injected, which resulted in
appearance of tumor in about 2 week time in all the animals. For
survival studies, less number of (10,000) B16F10 cells were injected
so as to observe the mice for longer time period.
Standardisation of dose-regimen of MIP
Initial experiments were done to find out the optimum dose and
treatment regimen of MIP which reduced the tumor growth
reproducibly. In these experiments, MIP, suspended in PBS, was
given by s.c route near the site of tumor cell injection at 7 day
interval and once the tumor started appearing it was given
peritumorally. Based on these studies, an optimum dose of 5610
6
bacilli/100 ml PBS per animal was selected. This optimum dose
was then further evaluated in two treatment regimens viz
therapeutic and prophylactic+therapeutic. In therapeutic treat-
ment, MIP was given at 7 day interval starting from one day after
tumor cell implantation. In prophylactic+therapeutic treatment,
one injection of MIP was given before implantation of melanoma
cells (prophylactic treatment) and then it was given at weekly
interval after implantation of melanoma cells (therapeutic
treatment). Progression of tumor was determined by measuring
tumor volume and protective efficacy of MIP was compared in
different groups.
Immunological studies
Mice were euthanized by CO2 asphyxiation. Single cell
suspension was prepared from spleen and tumor draining
lymphnodes by mincing the tissue through 70 mm mesh.
Erythrocytes were lysed by using the Gey’s solution. These cells
were restimulated with MIP antigen (sonicate supernatant of MIP)
or UV-irradiated B16F10 cells for 48 hrs. Culture supernatant was
analysed for different cytokines by ELISA. Cells were also studied
for the expression of specific cell surface markers by FACS.
Preparation of tumor infiltrating mononuclear cells
Subcutaneously implanted tumors when reached 400–500 mm
3
in size, were removed from mice and single cell suspensions were
prepared by enzymatic digestion. Resected tumors were weighed,
minced into small (1–2 mm
3) pieces with a scalpel, and incubated
in digestion mixture [5% FBS in RPMI 1640, 0.5 mg/ml
collagenase A (Roche Diagnostic), 0.2 mg/ml hyaluronidase, type
V (Sigma-Aldrich), and 0.02 mg/ml DNase I, (Sigma-Aldrich)] for
45 minutes at 37uC. The suspension was filtered using 40 mm cell
strainer (BD) and centrifuged at 280 g for 10 minutes. The pellet
was washed and resuspended in incomplete RPMI. Cell
suspension was layered over Ficoll-paque (GE Healthcare) and
centrifuged at 550 g for 30 minutes at 22uC. The buffy coat at
inter-phase was collected, cells were washed, and finally suspended
in PBS for further studies.
Flow cytometry
Single cell suspension of mononuclear cells obtained from
tumor mass, draining lymph node and spleen were stained with
Abs against various cell surface markers using standard staining
methods [14]. The following panel of commercially available and
directly fluorochrome conjugated anti-mouse monoclonal anti-
bodies were used in the study. FITC anti-mouse CD3, PE anti-
mouse CD4, PE anti-mouse CD8, FITC anti-mouse CD11c,
FITC anti-mouse CD14, PE anti-mouse CD40, PerCP anti-mouse
CD69, PE anti-mouse CD80, PE anti-mouse CD86, PE anti-
mouse NK1.1, and PE anti-mouse MHCII were purchased from
eBioscience or BD Biosciences. Samples were run on a BD LSR
(BD Bioscience) flow cytometer and data was analysed using
WinMDI 2.9 software.
Intracellular FoxP3 staining
Single cell suspensions prepared as described above, were used
for intracellular FoxP3 staining. Staining was performed using e-
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25424Figure 1. Standardisation of dose and treatment regimen of MIP. a) 30,000 B16F10 melanoma cells were injected in the right flank of C57BL/
6 mice on day 0. MIP dose in the range of 5.0610
4 to 1.0610
8 bacilli per 100 ml of PBS was given peritumorally at 7 day interval starting from day one.
Tumor growth was measured every 2 days. Control tumor bearing mice were injected saline. Dose of 5.0610
6 bacilli gave optimum protection. Data
are mean 6 SE values obtained from 8 mice/group. b) MIP at a dose of 5.0610
6 bacilli per 100 ml PBS was further evaluated using two different
treatment regimens viz. therapeutic (Group I) and prophylactic+therapeutic (Group II). Treatment schedule is shown in the figure. In comparison to
therapeutic regimen, prophylactic+therapeutic regimen was found to be more effective. This treatment regimen was therefore used for all the
subsequent studies. c) For survival studies less number (10,000) of B16F10 melanoma cells were injected subcutaneously in the right flank and MIP
treatment (as for Group II) was followed. Percent survival for observation period of 60 days is shown for control and MIP treated mice. (N) Control
group; (#) MIP treated group. Tumor volume=0.56large diameter6small diameter
2.* p ,0.05.
doi:10.1371/journal.pone.0025424.g001
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the instruction given by manufacturer. Briefly, cells were first
surface stained with PE anti-mouse CD4, washed in cold PBS and
suspended in freshly prepared fixation and permeabilization
solution for 2 hour at 4uC in dark. Cells were thereafter washed
with permeabilization buffer and incubated with FITC-anti mouse
FoxP3 for 1 hr. After washing with PBS, cells were analyzed in
flow cytometer.
NK cell cytotoxicity
NK cell cytotoxicity was evaluated using YAC-1 cells as target.
These cells were stained with CFSE at 2.0 mmol/ml concentration
for 5 minutes. Splenocytes collected from different groups of mice
were co-cultured with CFSE labelled YAC-1 cells at a ratio of 40:1
for 6 hours at 37uC/5% CO2. Target cell killing was determined
by flowcytometry on the basis of PI uptake. Percent cytotox-
icity=1006[No. of CFSE & PI double positive cells]4[(No. of
CFSE positive cells)+(No. of CFSE & PI double positive cells)].
CTL activity
Cytotoxic T lymphocytes (CTLs) were derived from splenocytes
by culturing them with UV irradiated B16F10 cells at ratio of 10:1
for 5 days. The culture was supplemented with recombinant
murine IL-2 (20 units/ml). After 5 days, CTLs were harvested and
cocultured with CFSE labelled B16F10 cells at effector: target
ratio of 40:1 for 6 hours. Target cell killing was determined by
flowcytometry on the basis of PI uptake. Percent cytotoxicity was
calculated as above.
MIP as an adjunct to chemotherapy
Drug Cyclophosphamide (CTX) was chosen for this study.
CTX was given by single i.p injection 7 days after tumor cell
implantation at a dose of 200 mg/kg body weight. Mice were
treated with CTX alone or CTX along with weekly injection of
MIP and groups were compared for progress in tumor, tumor
volume and survival of animals.
Statistical analysis
Statistical analyses were performed by a two-tailed student t-test
with GraphPad InStat software (GraphPad Software Inc.). Data
are represented as the mean 6 SEM or mean 6 SD as indicated
in respective figure legends.
Results
Optimisation of dose-regimen of MIP
Initial experiments were done to optimise the dose and regimen
of MIP treatment. B16F10 melanoma cells were injected
subcutaneously on the right flank of mice. Heat killed MIP
suspended in PBS was used for the treatment. MIP concentration
in the range of 5.0610
4 to 1.0610
8 per 100 ml was given
peritumorally at 7 day interval, starting from day one. It was
observed that lower dose of MIP (5610
4) and higher dose
(1.0610
8) was less effective while the dose in the range of 0.1
million to 10 million bacilli per injection gave good antitumor
response (Fig. 1a). Therefore, dose of 5.0610
6 bacilli/100 ml PBS
per animal was chosen for subsequent studies. This dose was then
further evaluated in two treatment regimens viz therapeutic (group
I), and prophylactic+therapeutic (group II). In prophylactic+ther-
apeutic regimen, one injection of MIP was given at ten day (210)
before tumor implantation, tumor was implanted on day 0, and
weekly treatment followed from day 1 onwards. In therapeutic
regimen, however, treatment started only after tumor cell
implantation. Both regimens, reduced the tumor growth as
compared to control group but, tumor growth was substantially
delayed and volume of tumors were significantly less in the Group
II (Fig. 1b). In control mice, tumor started appearing about 2 week
after tumor cell implantation, while in the mice vaccinated with
MIP, it started appearing only after 3 week of tumor cell injection
and tumor appeared in only 50–60% of mice. Therefore, in all
subsequent experiments a dose of 5.0610
6 bacilli per 100 ml was
used, and prophylactic+therapeutic treatment regimen was
followed.
After this we compared the survival of MIP treated and control
mice. For survival studies less number (10,000) of B16F10 cells
were injected and MIP treatment followed as for Group II. In MIP
treated mice, there was delayed tumor appearance and growth of
tumor was also slow. Consequently survival of MIP treated tumor
bearing mice was increased. While, in the control group, all the
mice died during the experimental observation period, only 25%
of the mice in the vaccinated group died during this period
(Fig. 1c).
MIP induced Th1 immune response in tumor bearing
mice
Th1 immune response plays a decisive role in protection from
tumor. Growing tumors, however, actively suppress the immune
response. We therefore evaluated the immune modulation induced
by MIP in tumor bearing mice. Splenocytes isolated from control
and MIP treated, tumor bearing mice were restimulated in vitro
with soluble antigens of MIP, and culture supernatant was
analysed for different proinflammatory and suppressive cytokines
by ELISA. Significantly high amounts of proinflammatory
cytokines, IL-12, IFN-c and TNF-a were found in the culture
supernatant of in vitro restimulated splenocytes from MIP treated
mice as compared to control mice (Fig. 2a). IL-2 and IL-15 were
found in moderate amount in both groups. Small amount of IL-10
was also induced on restimulation with MIP in both groups.
We also evaluated the phenotype of these splenocytes,
restimulated in vitro with MIP antigen. As shown in figure 2b,
there was significantly higher expression of CD86 and CD69,
indicating higher activation status of antigen presenting cells and
lymphocytes in MIP treated group as compared to control group.
Expression of CD80 and MHCII was comparable in both groups.
Tumors in MIP treated mice infiltrated with higher
number of lymphocytes, macrophages, and dendritic
cells
For understanding the mechanism of MIP mediated tumor
protection, distribution of immune cells was analysed in the tumor
Figure 2. Evaluation of MIP induced modulation of immune response. Splenocytes from control and MIP treated tumor bearing mice were
prepared after 3 weeks of tumor implantation and restimulated in vitro with MIP antigen for 48 hrs. a) Culture supernatants was analyzed for IL-12,
IFN-c, IL-2, IL-15, TNF-a and IL-10 by ELISA. Each bar represents the mean 6 SD of the two independent experiments (n=4). (%) unstimulated; (&)
restimulated with MIP antigen; *p,0.05; **p,0.01; ***p,0.0001. b) Activation of splenocytes after in vitro restimulation with MIP antigen.
Splenocytes were isolated, restimulated in vitro with MIP antigen for 48 hrs and were stained with respective Abs using standard staining method.
Cells were analyzed by flow cytometry. In comparison to control group, percentage of cells expressing CD69 and CD86 was higher in the MIP treated
group; ( ) unlabelled cells; (––) labelled cells.
doi:10.1371/journal.pone.0025424.g002
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MIP treated, tumor bearing mice. As shown in the figure 3a, there
was increase in the percentage of CD3+ and CD8+ T cells in the
tumor draining lymph node of MIP treated mice. When we
checked the activation status of immune cells, it was observed that
expression of CD80, CD86 and MHC II was significantly high in
the MIP treated group. Frequency of NK cells was comparable in
both groups.
Immune response in the tumor microenvironment is most
crucial factor to decide the prognosis of the disease. In general
higher infiltration of immune cells correlates with better prognosis,
so we analysed the tumor microenvironment for the same. About
four week after tumor cell implantation, mononuclear cells from
tumor mass were isolated and analysed by FACS. Tumors in MIP
treated mice were found to be infiltrated with higher number of
total immune cells (Fig. 3b). Since the tumor volume/weight was
significantly different in the two groups, we analysed it, as the
number of specific immune cells per gram of tumor. It was
observed that in MIP treated group, higher number of CD4+, and
CD8+ T cells were infiltrating the tumor (Fig. 3c). Similarly, the
number of NK and NKT cells infiltrating the tumor of treated
mice were also higher as compared to control mice.
Dendritic cells are potent antigen presenting cells and provide
necessary signal for activation and proliferation of lymphocytes.
Hence, we analysed the tumor infiltrating dendritic cells, which
were found in higher number in MIP treated group (Fig. 3c). Most
of these cells were in activated state, as evidenced by expression of
CD40, CD86 and MHCII. Macrophages, besides having antigen
presenting function, also show direct cytotoxicity against tumor
cells. In comparison to control group, we observed higher
infiltration of macrophages in the treated group and most of these
cells were expressing CD40, confirming M1 phenotype of these
cells, which is associated with better prognosis (Fig. 3c). Most of
these cells were also expressing CD86 and MHCII, providing
evidence of their activated state as compared to control group.
MIP treated mice had less number of regulatory T cells in
tumor and tumor draining lymph node
Regulatory T cells (Tregs) promote tumor growth by down-
regulating the anti-tumor immune response. Multiple mechanisms
for Treg mediated immune suppression have been established. We
studied the Treg cells in spleen, tumor draining lymph node and
tumor mass when the tumor reached 400–500 mm
3 in size. In spleen
we found comparable level of these cells in both treated as well as
untreated groups (Figure 4). However, in the tumor draining
lymphnodes and tumor microenvironment, Treg cell percentage
was lower in the MIP treated group. Treg cell expansion in the tumor
of control mice was substantial. While percentage of these cells was
nearing 50% of the total CD4+ cells in the tumor infiltrating
lymphocytes of control mice, it was just halfin the MIP treated group.
MIP treatment induced substantial antitumor immune
response
After studying the infiltration and phenotypic activation markers
of various immune cells, we studied the functional status of these
cells in the control or MIP treated tumor bearing mice, three week
after implantation of melanoma cells. First we evaluated the tumor
cell specific recall response. Mononuclear cells isolated from the
Figure 3. Phenotypic analysis of immune cells in tumor draining lymph node (TDLN) and Tumor. a) Inguinal lymph nodes were removed
from tumor bearing mice two weeks after tumor cell implantation. Single cell suspension were then analysed for expression of CD3, CD8, NK1.1,
CD80, CD86, and MHCII by flow cytometry. Each bar represents the mean 6 SD of the two independent experiments (n=3). b) Single cell suspension
obtained from buffy layer of ficoll gradient, of tumor cell suspension was analyzed for immune cell infiltration. Higher infiltration of immune cells was
observed in the MIP treated mice. c) Immune cell subtypes infiltrating the tumor. Number of specific cells (N) per gram of tumor was calculated by
formula: N=NSxNT/NAxW, where NS is the number of specific immune cells in the total acquired cells on flow cytometer; NA is the total no. of
acquired cells; NT is the total number of cells in the buffy coat on ficoll gradient; W is the tumor weight in gram. Tumors in MIP treated mice were
found to be infiltrated with higher number of lymphocytes, activated macrophages and dendritic cells; experiment was repeated twice; each group
having 6 animals. Data shown is mean of two independent experiments (mean 6 SD). *p,0.05; **p,0.01;
Np=0.05.
doi:10.1371/journal.pone.0025424.g003
Figure 4. Treg cells in spleen, tumor draining lymph node and
tumor mass. Single cell suspension from spleen, tumor draining
lymph nodes, and tumor of control and MIP treated tumor bearing mice
were analyzed for the expression of CD4 and FoxP3 by flow cytometry.
In tumor microenvironment and tumor draining lymph node, the
percentage of Treg cells were found to be lower in the MIP treated
group as compared to control. In spleen comparable level of these cells
were found in both, treated and untreated groups. ( ) CD4+ cells; (––)
CD4+FoxP3+ cells.
doi:10.1371/journal.pone.0025424.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25424Figure 5. Tumor cell specific immune response. a) Splenocytes from control and MIP treated tumor bearing mice at 3 weeks after tumor
implantation were in-vitro restimulated with UV-irradiated B16F10 melanoma cells for 48 hrs. Culture supernatants were then analyzed for the levels
of IL-12, IFN-c, TNF-a, IL-10, IL-1b and IL-6 by ELISA. Each bar represents the mean 6 SD of the two independent experiments (n=4); (%)
unstimulated; (&) restimulated; **p,0.01. b) NK cell cytotoxicity. To check NK cell cytotoxicity, CFSE labeled Yac-1 target cells were co-cultured with
splenocytes from control and MIP treated tumor bearing mice for 6 hrs. Target cell killing was analysed on the basis of PI uptake by flow cytometry.
Cytotoxicity was found to be higher in the MIP treated group as compared to control. c) CTL response against B16 melanoma cells. CTLs were derived
MIP Immunotherapy for Cancer
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B16 cells, which provided whole range of antigens present in B16
cells and supernatants were analysed for the cytokines. Proin-
flammatory cytokines IFN-c, TNF-a, IL-12 and IL-6 were found to
be significantly high in the B16 stimulated lymphocytes from MIP
treated group as compared to control group (Fig. 5a). IL-1b and IL-
10 were induced in response to stimulation with B16 cells in both
the groups but the amounts of cytokines secreted were moderate.
These findings confirmed that immune cells from MIP treated
group were functionally active and secreted proinflammatory
cytokines crucial for anti-tumor response.
We then analysed the cytolytic activity of NK cells and T cells.
These cells have potent cytolytic activity against tumor cells and
are crucial for protecting the host from neoplastic diseases. NK cell
cytotoxicity towards YAC-1 cells, as determined by flowcytometry,
was found to be higher in the MIP treated group as compared to
control (Fig. 5b). Similar observation was made when in vitro
generated CTL were co-cultured with B16F10 target cells. CTL
activity was found to be higher in the MIP treated group as
compared to control untreated group (Fig. 5c). These results
confirm that MIP treatment in the tumor bearing mice results in
functional activation of T cells and NK cells which along with
other factors results in regression of tumor.
Efficacy of MIP as an adjunct to chemotherapy
To explore the use of MIP in real life situation, we evaluated its
efficacy as an adjunct to chemotherapy. Cyclophosphamide, an
anti-cancer drug used for the treatment of lymphomas, leukemias,
and solid tumors was chosen for this study. Mice were treated with
cyclophasphamide alone (CTX group) or cyclophasphamide along
with MIP (CTX+MIP group) and were observed for growth of
tumor (Fig. 6). In the control group, tumor began to appear at 2–3
week after tumor cell implantation. In CTX group, there was
delay in tumor growth and it started appearing only at 4–5 week
after tumor cell implantation. But in the group where MIP was
given along with CTX, tumor growth was significantly less and 4
out of 8 mice remained free from tumor for the experimental
observation period and 2 mice had very small tumor growth. In
control group all the mice developed tumor and died of the tumor
burden whereas, only one mice in the CTX+MIP group died
during this time.
Discussion
Although progress has been made in the field of tumor
immunology in the past decade but the vaccines were mostly
evaluated based on surrogate end points like histologic evidence of
tumor necrosis or lymphocyte infiltration rather than objective
tumor regression [15,16]. In our study we have objectively studied
from splenocytes of control and MIP treated tumor bearing mice by culturing with UV-irradiated B16F10 cells and rIL-2 for 5 days. Cytotoxicity was
determined by co-culturing CTLs with CFSE-labeled B16F10 target cells. % Cytotoxicity=1006[No. of CFSE & PI double positive cells]4[(No. of CFSE
positive cells)+(No. of CFSE & PI double positive cells)].
doi:10.1371/journal.pone.0025424.g005
Figure 6. Antitumor activity of MIP given with Cyclophosphamide. Mice were treated with CTX alone or CTX along with MIP (CTX+MIP). CTX
was given intraperitoneally on day 7th after tumor cell implantation at a dose of 200 mg/kg in both groups. In CTX+MIP group, MIP injection was
given at 1 week interval as shown in figure. Each line in graph represents tumor growth curve of individual mice. MIP given along with CTX therapy
showed higher protection as compared to CTX alone. 4 out of 8 mice were free of tumor and tumor volume was also less in this group. * symbolize
the death of mice on the corresponding day. Number in parenthesis indicates number of mice showing tumor out of 8 mice.
doi:10.1371/journal.pone.0025424.g006
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logical parameters.
Results of this study provide evidence of immunotherapeutic
potential of MIP in mouse model of tumor. We chose mouse
syngenic B16F10 melanoma cells for this study as this is very
aggressive tumor and poorly immunogenic. MIP was compared
for immunotherapeutic efficacy using two different treatment
regimens. In therapeutic regimen, MIP was given after implan-
tation of melanoma cells. In prophylactic+therapeutic regimen,
one injection was also given before tumor implantation and rest
were given as for therapeutic regimen. Decrease in tumor growth
was observed in both groups as compared to control, but in the
later group, growth of tumor was delayed and volume of tumor
was significantly less. There was no tumor growth in about 40–
50% of mice which resulted in the prolonged survival of the
treated mice as compared to control.
Since 1882, when Coley used a bacterial preparation (Coley
toxins) to treat sarcomas, there has been evidence that bacterial
products can beneficially affect the course of several cancers.
BCG has been used extensively with some definite but limited
anti-tumor efficacy [17,18,19]. Intravesical administration of live
BCG is successful for cancer of urinary bladder, but is associated
with significant toxicity and is ineffective in 30–40% of cases.
Hence, other mycobacterial strains have also been evaluated for
their anticancer efficacy. It has been reported that closely related
mycobacterial strains demonstrate contrasting levels of efficacy as
antitumor vaccine as they are processed differently inside the
antigen presenting cells [10]. MIP and BCG have significant
differences viz. growth rate of BCG is slow, while MIP is fast
grower [20]. There are structural differences in the cell wall of
fast and slow-growing mycobacteria [21,22], which might affect
their intracellular processing and thus the immune response
induced.
It is generally accepted that the generation of an effective anti-
tumor and anti-infective immune response requires antigen
presenting cells to prime cytotoxic T cells and CD4+T cells. It is
reported that established tumors can be eradicated by CD8+T cell
adoptive immunotherapy [23]; and extensive T cell infiltrates are
commonly seen in tumors undergoing immunologic rejection [15].
We observed higher frequency as well as higher expression of
phenotypic activation markers on macrophages and T cells of MIP
treated mice which also reflected in their enhanced functional
activity. In addition to induction of IFN-c, TNF-a and IL-12
secretion, higher NK cell and CD8+ T cell cytotoxic activity was
observed. NK cells have been shown to have important role in
anti-tumor immune response. It has been shown that patients with
high level of NK cell infiltration had better prognosis than those
with low level of NK cells in colon and lung carcinomas [24,25].
An interesting finding of this study was that along with
activation of antigen presenting cells, NK cells and T cells,
peritumoral injection of MIP also resulted in significantly less
number of tumor infiltrating regulatory T cells. Proportion of
regulatory T cells in the spleen was not significantly different in the
MIP treated and control group and was about 20% of the total
CD4+ cells. It is reported that expansion of Treg cells inside the
tumor is substantial and occur to lesser extent in the spleen and
lymphnodes and that too in the late stages of tumor growth [26].
Treg cells inhibit the development and effector functions of tumor-
specific T cells. They accumulate in the tumor microenvironment
and suppress cytotoxic T cell responses against the tumors [27,28].
Elimination of these suppressor T cells from tumor uncovers
natural antitumor response. [28,29]. Strategy that combines
modulation of suppressive factors along with the activation of
pro-inflammatory Th1 type of response within the tumor
microenvironment could be a potentially effective approach which
could be combined with chemotherapy to combat cancer
successfully.
Hence, we explored the complementary approach of combina-
tion of immunotherapy and chemotherapy to improve the
anticancer efficacy of the both. We observed synergistic activity
of CTX and MIP treatment. It is suggested that the mechanism of
this form of immunotherapy is, at least in part due to immune
modulation i.e. selective enhancement of Th1 activity. Other
factor could be the TNF-a secretion in the tumor microenviron-
ment, by MIP immunisation, which is reported to increase the
permeability of tumor vessels for passage of cytotoxic drugs [30].
We also observed that MIP injection even if given at the dorsally
opposite side of tumor, reduced tumor growth as compared to
control. A valuable property of MIP immunotherapy is its virtual
lack of adverse side effects as this has been administered to
thousands of patients in clinical trials of tuberculosis, and leprosy
with no reported problems [31,32]. Another great advantage is the
low cost of production.
In summary, our findings establish the potential antitumor
efficacy of MIP. This study provides evidence into how MIP
therapy alters the immunosuppressive tumor milieu to immuno-
logically active one, which ultimately results in tumor regression.
There is a need to further understand the MIP mediated
modulation of immune response at molecular level. We will
further study the use of MIP as an adjunct to chemotherapy since
combination therapy is the way to control cancer effectively.
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